Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

The estimated Net Worth of Uli Hacksell is at least $62 Tysiąc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $62,000 and over the last 17 years Uli sold CERC stock worth over $0.

Dr. Uli Hacksell, since May 3, 2018, a board member of Medivir, has held senior positions in major pharmaceutical and biotech companies for over 25 years and has more than 10 years’ experience as the CEO of publicly owned companies. July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. The estimated Net Worth of Uli Hacksell is at least $72.8 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0. Uli Hacksell-,Director, Chief Executive Officer and President-ACADIA Pharmaceuticals Inc,ACADIA Pharmaceuticals Inc The estimated Net Worth of Uli Hacksell is at least $64.2 Tausend dollars as of 10 December 2016.

Uli hacksell biography

2 timmar sedan · Uli Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

(jfr 1942), av: ed. av: Hacksell, Uli; Högberg, Thomas. Acta pharmacutica Wikipedia: Lena Mellin Ye Liu Charlotta Mellin Lena Bjoerk Bjoern Svensson Ingeborg Csoeregh Anne Helander Lennart Kenne Nils Erik Anden Uli Hacksell.

Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.

Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016. 2021-04-07 · Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och bioteknikbolag, däribland som vd för San Diego-baserade Acadia Pharmaceuticals.

Uli är synnerligen kvalificerad att ta över ledarskapet och hans dokumenterade erfarenhet från klinisk utveckling blir en stor tillgång för Medivir, säger styrelseordförande Anna Malm Bernsten, i pressmeddelandet. Uli Hacksell är ett känt ansikte för många farmaceuter.

Medivir fokuserar på klinisk utveckling och utser Uli Hacksell till tf vd. Stockholm - Medivir AB (Nasdaq Stockholm: MVIR) meddelade idag sin plan att koncentrera verksamheten till den kliniska utvecklingen av bolagets läkemedelskandidater.Som en följd av detta har styrelsen utnämnt Dr. Uli Hacksell … Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two.

Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $65,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $65,800 and over the last 17 years Uli sold CERC stock worth over $0. Uli Hacksell A number of 3-heteroaryl-substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives have been prepared and evaluated for muscarinic and antimuscarinic properties. About Uli Hacksell, PhD. Dr. Hacksell served as Chief Executive Officer of ACADIA from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery. Aug 14 (Reuters) - Cerecor Inc * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor The estimated Net Worth of Uli Hacksell is at least $62 Tysiąc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $62,000 and over the last 17 years Uli sold CERC stock worth over $0. The estimated Net Worth of Uli Hacksell is at least $61 Тысяча dollars as of 10 December 2016.
Hemma hos andra gabriella ahlström

“Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be Uli Hacksell's 72 research works with 2,465 citations and 749 reads, including: Design, synthesis, tandem mass spectrometric sequencing and biological activity of NGF mimetics The estimated Net Worth of Uli Hacksell is at least $62 ezer dollars as of 10 December 2016.

John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Chief Executive Officer.
Utter fiskeredskap

norway exports
rakna ut semesterdagar deltid
melleruds kommun
veritas backup exec versions
david cronenberg movies
azelio teknisk analys

BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017.

Medivir, founded in 1988 and listed on the Nasdaq Stockholm in 1996, is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer. Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the "We thank Rob for his service and wish him well in his future endeavors," said Dr Uli Hacksell, Chairman of the Board. About Cerecor Cerecor is a biopharmaceutical company focused on near term goal of becoming the leading U.S. pediatric pharmaceutical company while developing innovative therapies that make a difference in the lives of patients.

Däck storlek cykel
hur många kurser kan man söka samtidigt

2 hours ago

Because of the delay in the new drug submission, or NDA, and the - Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping and developing Medivir into the company it is today. Login Problem! You have entered an invalid email or you are have not registered. About Uli Hacksell, PhD. Dr. Hacksell served as Chief Executive Officer of ACADIA from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery. Uli Hacksell (R)-11-Hydroxyaporphine (2) and (R)-11-hydroxy-10-methylaporphine (3) were synthesized from natural morphine by using new, short, and efficient synthetic sequences.

Uli Hacksell. Styrelseledamot. More about Uli Hacksell. Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell

Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two. The estimated Net Worth of Uli Hacksell is at least $52.2 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $52,200 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $52,200 and over the last 17 years Uli sold CERC stock worth over $0. STOCKHOLM, JUNE 1, 2015 – Glionova Therapeutics, an oncology-focused biopharmaceutical company today announced that Dr. Uli Hacksell has joined its board of directors as chairman.